CD44 and acute lymphoblastic leukemia: Our findings show the common role of BRD4 in the NOTCH1-, MYC-, and CD44-regulatory axis and we propose that BRD4 is a single target that can be used to disrupt all these pathways simultaneously eliminating T-ALL LICs.